Inventor · disambiguated record
Ronghua Zhao
Also filed as: ZHAO RONGHUA
6 granted patents·3 pending applications·2 citations·filing 2016–2023
68Inventor score
Top patents by PatentIndex Score
9 records- 0167US2024100106A1Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2023·Application pending·0 cites
- 0266US2022339220A1Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2022·Application pending·0 cites
- 0365US10980859B2In vivo individualized systemic immunotherapeutic method and deviceHANGZHOU CONVERD CO LTD·Filed 2016·Granted Apr 20, 2021·1 cites·9 claims
- 0462US11071737B2Drug inclusion complex, preparation thereof, and preparation method thereofGUANGZHOU XIANGXUE PHARMACEUTICAL CO LTD·Filed 2016·Granted Jul 27, 2021·1 cites·9 claims
- 0560US11806374B2Isolated recombinant oncolytic adenoviruses, pharmaceutical compositions, and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2018·Granted Nov 7, 2023·0 cites·26 claims
- 0660US11446345B2Therapeutic agents and uses thereof for drugs for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2018·Granted Sep 20, 2022·0 cites·15 claims
- 0743US2020289591A1Isolated Recombinant Oncolytic Poxvirus, Pharmaceutical Composition, and Use Thereof in Treatment of Tumors and/or CancerHANGZHOU CONVERD CO LTD·Filed 2018·Application pending·0 cites
- 0841US11357804B2Application of oncolytic viruses as immunostimulants for treatment of tumors and/or cancersHANGZHOU CONVERD CO LTD·Filed 2018·Granted Jun 14, 2022·0 cites·5 claims
- 0933US11007141B2Oral preparation and preparation method thereofGUANGZHOU XIANGXUE PHARMACEUTICAL CO LTD·Filed 2016·Granted May 18, 2021·0 cites·21 claims
Join the waitlist — get patent alerts
Get an alert when Ronghua Zhao files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →